SYNTHESIS AND PHARMACOLOGICAL INVESTIGATION OF SOME DERIVATIVES OF 1,2,3,4-TETRAHYDROPYRIMIDINE5-CARBOXYLIC ACID

E. L. Khanina, G. O. Silinietse, Ya. Ya. Ozol, G. Ya. Dubur, and A. A. Kimenis

UDC 615.31:547.854.9

Derivatives of 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid exhibit antitumor and antiviral activity [1-3]. We first discovered that amides of that acid have hypotensive and coronary dilatation properties [4]. In order to extend the search for substances which affect the blood circulation system, we synthesized new β -aminoethyl esters of 2-oxo-4-aryl-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid. Those compounds were obtained through a nucleophilic substitution reaction of the chlorine atom in the corresponding β -chloroethyl esters I-III by an amine residue. The β -chloroethyl esters of 2-oxo-4-aryl-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid were obtained by a modification of the Bidzhinelli condensation [5] from urea, benzaldehyde or its derivative, and the β -chloroethyl ester of aceto-acetic acid.

$$\begin{array}{c} NH_2 + \text{ Ar CHO} + \text{ CH}_2\text{COCH}_2\text{COOC}_2\text{H}_4\text{Cl} \\ -\text{C=O} \\ NH_2 \\ \hline \\ NH_3 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_3 \\ \hline \\ NH_4 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_3 \\ \hline \\ NH_4 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_3 \\ \hline \\ NH_4 \\ \hline \\ NH_2 \\ \hline \\ NH_2 \\ \hline \\ NH_3 \\ \hline \\ NH_4 \\ \hline \\$$

The structure of the compounds obtained was established by a combination of UV and IR spectra (Table 1).

The chlorine of compound I-III has a comparatively low activity in reactions with amines, and for that reason the amination is carried out in the presence of potassium iodide. Dimethylformamide is used as a solvent, which as a result of its high solvating ability shows catalytic activity in nucleophilic substitution reactions [6].

Compounds IVa-d were investigated pharmacologically, and the results of those studies are shown in Table 2. In acute experiments on narcotized cats it was shown that all of the investigated substances lower the arterial pressure, but their hypotensive action is less than that of papaverine. In doses of 1 to 5 mg/kg these substances have no effect on the hemodynamic effects of epinephrine, acetylcholine and serotonin. Compound IVa lowers the hypotensive reaction to the stimulation of the peripheral end of the vagus nerve. ED_{50} is 5.4 (3.1 to 7.7) mg/kg.

The effect of these substances on coronary blood circulation was investigated by the method of N. A. Kaverina [7] on cats, and by the flowmetric method [8] in experiments on dogs. In doses of 1 to 5 mg/kg these substances do not alter the coronary blood flow. The method of Papp and Szekeres [9] was used to determine the effect of these substances on the pituitrin spasm of coronary vessels. In a series of experiments compound

Institute of Organic Synthesis, Academy of Sciences of the Latvian SSR, Riga. Translation from Khimiko-Farmatsevticheskii Zhurnal Vol. 12, No. 10, pp. 72-74, October, 1978. Original article submitted Feb. 20, 1978.

TABLE 1 Derivatives of 2-Oxo-4-arvl-6-methyl-1.2.3.4-tetrahydropyrimidine-5-carboxylic Acid

Melting															
mid \(\beta_{1}\) point, \(\beta_{1}\) C H N Hal C H N Hal formula P 49 178—80 57,12 5,40 12,87 9,90 57,05 5,13 12,08 9,50 C ₄ H ₁₄ N ₂ O ₃ CI 205,21 40 203—5 50,18 4,25 13,01 10,79 49,71 4,15 12,97 10,44 C ₄ H ₁₄ N ₂ O ₃ CIB 205,21	Com	Yield.	Melting	H	onno.	%		J	alcula	ted, %		Empirica1	UV Spectrum	trum	IR Spectrum
178-80 57,12 5,40 12,87 9,90 57,05 5,13 12,08 9,50 C ₁₄ H ₁₅ N ₂ O ₅ CI 203	punod	%	point, C	ပ	н	z	Hal	ပ	H	z	Hal	formula	λ _{max} , mn	lg 8	'C=O' cm"I
49 178—80 57,12 5,40 12,87 9,90 57,05 5,13 12,08 9,50 C ₄ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ 4H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ C ₁ H ₃ N ₃ O ₃ C ₁ H ₃ N							-		, ,	- 50	1		100		
640 203.—5 50,18 4,25 13,01 10,79 49,71 4,15 12,97 10,44 C44H4,N ₉ O ₆ CI 244 204.—6 44,29 3,89 7,93 31,12 43,18 3,90 7,75 30,90 C ₁ 3H4,N ₉ O ₈ CI 71 131.—3 66,50 7,34 12,24 66,45 12,24 C ₁ 4H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₉ O ₈ CI 71 12,17 C ₁ 6H ₂ N ₁ O ₈ CI 71 12,17 C ₁	_	49	178-80	57,12	5,40	12,87	6,90	57,05	5,13	7,08	9,50	C14H15N2O3C1	205, 218 sh. 286	4,	01/100
44 204—6 43,29 3,89 7,93 31,12 43,18 3.90 775 30,90 C ₃ H ₂ N ₃ N ₃ O ₃ ClBr 71 131—3 66,56 7,34 12,53 — 66,45 7,34 12,24 — C ₃ H ₂ N ₃ O ₃ -18 59 166—7 65,41 7,95 12,17 — 65,23 7,60 12,17 — C ₃ H ₂ N ₃ O ₄ 87 148—50 68,32 6,23 17,60 12,69 — C ₃ H ₂ N ₃ O ₄ 75 51—3 58,49 6,25 14,79 — 68,36 6,02 11,96 — C ₃ H ₂ N ₃ O ₄ 42 124—6 55,63 5,14,59 — 56,38 5,68 14,36 — C ₃ H ₂ N ₃ O ₄ 63 172—4 57,23 6,64 14,60 — 57,44 6,43 14,85 — C ₃ H ₂ N ₃ O ₆ 55 112—4 57,23 6,64 14,60 — 57,44 6,43 14,85 — </td <td>=</td> <td>3</td> <td>2035</td> <td>50,18</td> <td>4,25</td> <td>13,01</td> <td>10,79</td> <td>49,71</td> <td>4,15</td> <td>12,97</td> <td>10,44</td> <td>C,4H,4N,3O,C!</td> <td>205, 218 sh. 274</td> <td>4, C,</td> <td>1740,1718</td>	=	3	2035	50,18	4,25	13,01	10,79	49,71	4,15	12,97	10,44	C,4H,4N,3O,C!	205, 218 sh. 274	4, C,	1740,1718
71 131—3 66,50 7,34 12,53 — 66,45 7,34 12,24 — C, H. S.N.J. J.	111	44	2046	43.29	3.89	7.93	31.12	43.18	3,90	7,75	30,90	C, H, N,O,CIBr	203, 234, 292		1730,1700
59 146—7 62,42 6,80 11,81 — 62,59 6,71 12,17 — C ₁₈ H ₂ N ₃ O ₄ 87 148—7 66,31 17,95 12,17 — 66,22 17,60 — C ₁₈ H ₂ N ₃ O ₄ 87 148—6 68,32 17,50 11,59 — C ₁₈ H ₂ N ₃ O ₄ C ₁₈ H ₂ N ₃ O ₄ 75 151—3 58,49 6,23 14,79 — 66,02 11,96 — C ₁₈ H ₂ N ₃ O ₄ 75 151—3 56,49 6,27 14,06 — 55,38 5,68 14,38 — C ₁₈ H ₂ N ₃ O ₆ 63 172—4 57,23 6,64 14,60 — 57,44 6,43 14,85 — C ₁₈ H ₂ N ₃ O ₆ 85 112—4 57,23 6,64 14,60 — 57,44 6,43 14,85 — C ₁₈ H ₂ N ₃ O ₆ 87 142—7 55,06 5,54 9,86 19,01 52,99 19,01 18,97 18,98	\ \	1/	131-3	66.50	7.34	12,53	.	66.45	7.34	12.24	-	Ç	205, 218sh. 298	4,1	1730,1710
90 105—7 65,41 7,95 12,17 65,23 7,60 12,69 C ₁ C ₁ H ₂ N ₃ O ₃ 75 148—50 68,32 6,23 14,79 68,36 6,02 11,96 C ₂ C ₃ H ₂ N ₃ O ₃ 75 151—3 58,49 6,25 14,79 58,34 6,33 14,43 C ₃ C ₃ H ₂ N ₃ O ₃ 72—4 57,23 6,64 14,60 57,44 6,43 14,85 C ₃ C ₃ H ₂ N ₃ O ₃ 85 144—6 69,7,23 6,64 14,60 57,44 6,43 14,85 C ₃ C ₃ H ₂ N ₃ O ₃ 87 45—7 55,66 5,54 9,86 19,01 52,69 5,90 18,47 C ₃ H ₂ N ₃ O ₃ 87 135—7 55,66 5,74 6,83 14,85 C ₃ H ₃ N ₃ O ₃ 88 19,01 18,20 5,86 19,01 52,69 10,34 19,47 C ₃ H ₃ N ₃ O ₃ 89 19,01 18,20 5,86 18,20 18,57 C ₃ H ₃ N ₃ O ₃ 89 19,01 18,20 5,86 18,20 18,57 C ₃ H ₃ N ₃ O ₃ 89 19,01 18,20 18,20 18,57 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,20 18,57 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,20 18,57 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,20 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,20 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,50 18,50 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,50 18,50 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,50 18,50 18,50 18,50 18,57 C ₃ H ₃ N ₃ O ₃ 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50 18,50 80 19,01 18,50 18,50 18,50	1/5	55	146-7	62.42	6,80	18.11	1	65,29	6,71	12,17	j		205,218 sh 288	4,3, 4,1, 4,0	1720,1695
87 148—50 68,32 6,23 11,59 — 68,36 6,02 11,96 — G,04 Landon G,04 La	!\c	6	1057	65.41	7.95	12,17	1	65.23	7.60	12,69	ا	, O	205, 218 sh. 288		1730,1710
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	P.A.	22	148-50	68,32	6,23	1.59	ŀ	68,36	6,02	11,96		H, N, O,	205, 244, 289		1720,1710
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	\ 8	22	151-3	58.49	6.25	14.79	1	58,74	6,23	14,43	j	H ₂₄ N ₄ O ₆	203, 215 sh. 275		1730,1710
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	ΛÞ	42	124-6	55,65	5,71	14.05	1	55,38	5,68	14,35	.]	H ₂₂ N ₄ O	203, 215 sh. 275		1740,1720
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	\ \ \	3	172-4	57.23	6.64	14.60	1	57.44	6,43	14,85		H.N.O.	203, 218 sh. 279		1740,1720
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	ν		144-6	60,75	5.08	14.19	1	09,09	5.08	14,13	ļ	C, H, N,O	203, 253, 275		1740,1720
87 1457 53,06 5,54 9,86 19,01 52,69 5,90 10,34 19,47 C, H, N, O, Br 61 1357 50,50 5,27 9,80 18,06 50,95 5,123 9,90 18,83 C, H, H, N, O, Br 63 19031 55,64 4,99 9,47 18,20 55,89 4,68 9,76 18,57 C, H, N, O, Br	Ve	£	112-4	57.23	6,64	14.60	I	57.44	6,43	14,85]	C, H, N,O	203, 218sh, 275		1740,1720
61 135—7 50,50 5,27 9,80 18,60 50,95 5,23 9,90 18,83 C, H ₂₀ N ₃ O ₄ Br 68 199—31 55,64 4,49 9,47 18,20 55,89 4,68 9,76 18,57 C ₂ ,H ₂₀ N ₃ O ₂ Br	Va	87	1457	53.06	5.54	98.6	19,01	52.69	5,90	10,34	19,47	C, H. N.O. Br	203, 230, 286		1730,1710
68 199—31 55 64 4.49 9.47 18.20 55.82 4.68 9.76 18.57 C. H. N. O. Br	Λβ	5	135-7	50.50	5.27	9.80	18,60	50,95	5.23	9.30	18,83	C, H. N.O. Br	203, 230, 286		1730,1710
- 19 - 2 - 19 - 19 - 19 - 19 - 19 - 19 -	Vc.	8 9	129-31	55,64	4,49	9,47	18,20	55,82	4,68	9,76	18,57	C20H20N3O3Br	203, 234, 286		1730,1710

TABLE 2. Effect of Compounds IVa-d on the Cardiovascular System and Their Acute Toxicity

Compound	ED ₃₀ hypotensive effect, mg/kg	Effect on the spasm of rabbit's ear produced by epinephrine	LD ₅₀ for white mice with intraperitoneal administration, mg/kg
IVa IVb IVc IVd Papaverine	4,9 (1,8÷8,0)	No change	260 (240—325)
	9,0 (5,5÷12,4)	(10 ⁻⁶ -10 ⁻⁵) *	250
	0,5	Reduced (10 ⁻⁵) *	500
	3-5	Reduced (10 ⁻⁵) *	1000
	0,27	Reduced (10 ⁻⁵) *	91 (82—101) [10]

^{*}Concentration of substance (in g/liter).

IVa in doses of 0.5 to 1.0 mg/kg and compound IVb in doses of 5 mg/kg reduced the ECG changes produced by pituitrin. In experiments on isolated vessels of rabbit's ear compounds IVb and IVd, in concentrations of 10^{-5} g/liter, reduced the vessel spasm produced by epinephrine. In this respect these compounds do not differ from papaverine, but they are considerably less toxic (compound IVd is more than 10 times less toxic).

The finding in compounds IVa-d of hypotensive and spasmolytic properties provides the basis for further investigation of compounds of this type.

EXPERIMENTAL

Chemical

UV spectra were obtained on a Specord UV-Vis spectrophotometer in ethanol, at concentrations of 5×10^{-5} mmole. IR spectra were recorded on the UR-20 instrument in mineral oil mulls.

 $2-\text{Oxo}-4-\text{phenyl}-5-(\beta-\text{chloroethoxycarbonyl})-6-\text{methyl}-1,2,3,4-\text{tetrahydropyrimidine}$ (I). To a solution of 0.6 g (0.01 mole) of urea in 30 ml of absolute ethanol we added 1.65 g (0.01 mmole) of β -chloroethyl ester of acetoacetic acid and 1.05 g (0.1 mmole) of benzaldehyde. The mixture was acidified with concentrated hydrochloric acid and refluxed for 5 h. Compound I separated upon cooling. Compounds II and III were obtained by the same method (see Table 1).

2-0xo-4-phenyl- $5-(\beta$ - piperidinoethoxy carbonyl)-6-methyl-1,2,3,4-tetrahydropyrimidine (IVa). To a solution of 1.4 g (0.05 mmole) of compound I in 25 ml of dimethylformamide, we added 0.85 g (0.1 mmole) of piperidine and potassium iodide in an equimolar ratio. The mixture was boiled, cooled, and diluted with water. A colorless residue was obtained, which was crystallized from benzene. When hydrogen chloride was bubbled through, we obtained hydrochloride IVa. Compounds IVb-d, Va-e, and VIa, b, d were obtained by similar reaction.

LITERATURE CITED

- 1. R. Hull and G. Swain, Brit. Pat. No. 868,030 (1961).
- 2. D. McKinstry and E. H. Reading, J. Franklin Inst. 237, 203 (1944).
- 3. H. A. Rutter and L. O. Gustafson, J. Franklin Inst., 258, 413 (1954).
- 4. G. Ya. Dubur, E. L. Khanina, and R. O. Vitolin', Inventor's Certificate No. 422735 (USSR), (1973); Otkrytiya, 1974, No. 13, p. 93.
- K. Folkers, H. I. Harwood and T. B. Johnson, J. Am. Chem. Soc., <u>54</u>, 3751 (1932).
- 6. Ya. Ya. Ozol, S. K. Germane, G. Ya. Dubur, et al., Khim. Farm. Zh., 10, No. 2, 63 (1976).
- 7. N. V. Kaverina, Farmakol. Toksikol., 21, 39 (1958).
- 8. R. Charlier, Antianginal Drugs, Berlin, 1971.
- 9. I. Papp and L. Szekeres, Arch. Int. Pharmacodyn., 160, 147 (1966).
- 10. M. A. Britse, D. R. Tsirule and A. A. Kimenis, Izv. AN Latv. SSR, No. 7, 125 (1966).